AIM ImmunoTech Balance Sheet Health
Financial Health criteria checks 2/6
AIM ImmunoTech has a total shareholder equity of $2.9M and total debt of $2.7M, which brings its debt-to-equity ratio to 93.8%. Its total assets and total liabilities are $13.6M and $10.7M respectively.
Key information
93.8%
Debt to equity ratio
US$2.73m
Debt
| Interest coverage ratio | n/a |
| Cash | US$7.20m |
| Equity | US$2.91m |
| Total liabilities | US$10.68m |
| Total assets | US$13.59m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AIM's short term assets ($7.6M) do not cover its short term liabilities ($10.1M).
Long Term Liabilities: AIM's short term assets ($7.6M) exceed its long term liabilities ($576.0K).
Debt to Equity History and Analysis
Debt Level: AIM has more cash than its total debt.
Reducing Debt: AIM's debt to equity ratio has increased from 31.6% to 93.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AIM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AIM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.7% each year